CompletedNot Applicable

Effect of Nutritional Supplementation With Turmeric on the Cognitive Performance of Subjects With Metabolic Syndrome

Italy85 participantsStarted 2022-04-08

Plain-language summary

The EPICURO study aims to demonstrate the beneficial effects of a 6-month dietary supplementation with an improved bioavailable turmeric (MERIVA®) on inflammatory, oxidative and metabolic parameters together with cognitive performance, potentially resulting in the reduction of the risk of cognitive decline in subjects, male and female, with Metabolic Syndrome. The results obtained will provide novel insights on MERIVA® for improving the prevention of age-related cognitive decline and Alzheimer's disease.

Who can participate

Age range60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Presence of abdominal obesity (waist circumference\> 94 cm for males and\> 80 cm for females).
✓. Fasting blood glucose ≥ 100 mg / dl.
✓. Triglycerides ≥ 150 mg / dl.
✓. HDL cholesterol \<40 mg / dl for males, \<50 mg / dl for females.
✓. Arterial hypertension (≥ 135/85 mmHg).

What they're measuring

Change from Baseline of Mini-Mental State Examination (MMSE) Test

Timeframe: Change from Baseline (T0) to 6 months of treatment (T6) and 12 months of treatment (T12).

Change from Baseline of Montreal Cognitive Assessment (MOCA) Test

Timeframe: Change from Baseline (T0) to 6 months of treatment (T6) and 12 months of treatment (T12).

Trial details

NCT IDNCT04705220

SponsorIndena S.p.A

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2025-10-16

View on ClinicalTrials.gov More Mild Cognitive Impairment trials